Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rifaximin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 5/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 4/20 | 1.00 |
| ▸ | ABCC2 | Q92887 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 3/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 2/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | NPY1R | P25929 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 2/20 | 1.00 |
| ▸ | BDKRB2 | P30411 | 2/20 | 1.00 |
| ▸ | AVPR2 | P30518 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rifaximin SCHEMBL16351426 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL124066 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL16229249 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL874028 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL14677545 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL13897021 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL23314507 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL9397878 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL17930616 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL124067 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180221296-A1 | INTRASITE ADMINISTRATION AND DOSING METHODS AND PHARMACEUTICALS FOR USE THEREIN | HKL Medical, LLC | 2018-08-09 | — | — | US | disclosed |
| US-8404704-B2 | Use of polymorphic forms of rifaximin for medical preparations | ALFA WASSERMANN S.P.A. (IT) | 2013-03-26 | — | — | US | disclosed |
| US-20120059023-A1 | USE OF POLYMORPHIC FORMS OF RIFAXIMIN FOR MEDICAL PREPARATIONS | ALFA WASSERMANN, S.P.A. (IT) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221296-A1 | INTRASITE ADMINISTRATION AND DOSING METHODS AND PHARMACEUTICALS FOR USE THEREIN | CD68, SEC62, ANTXR2 | ABCB11 973/4885ABCC4 2738/4885ABCC2 2359/4885 |
| US-20120059023-A1 | USE OF POLYMORPHIC FORMS OF RIFAXIMIN FOR MEDICAL PREPARATIONS | RIF1, UGT1A1, IFNAR1 | ABCB11 18/4885ABCC4 611/4885ABCC2 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.